Form 4: Iovance Biotherapeutics COO Igor Bilinsky Reports Stock Transactions
SEC Form 4 Filing
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On July 15, 2024, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, had 2,813 restricted stock units (RSUs) vest.
- The company withheld 1,428 shares at a price of $8.68 to satisfy tax withholding requirements.
- Following these transactions, Bilinsky directly owns 41,143 shares of common stock and 5,626 restricted stock units.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions, reflecting standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders are informed about the stock transactions of a key executive.
- Employees may be interested in the details of executive compensation.
Key Dates
| Date | Description |
|---|---|
| January 14, 2022 | Date of grant for the reported RSUs |
| 07/15/2024 | Date of RSU vesting and tax withholding. |
| 07/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.